LVPEIi008-B

LVIP04-SD1-2

General

Cell Line

hPSCreg name LVPEIi008-B
Cite as:
LVPEIi008-B (RRID:CVCL_D6MX)
Alternative name(s)
LVIP04-SD1-2
Cell line type Human induced pluripotent stem cell (hiPSC)
Similar lines
LVPEIi007-B
(LVIP04-SD1-1)
Donor diseases:
Stargardt disease
FRIMOi004-A
(STGD2_ FiPS4F1.7)
Donor diseases:
Stargardt Disease
CUIMCi005-A
(BB#2, BB9068#2)
Donor diseases:
Stargardt Disease
FRIMOi003-A
(STGD1_ FiPS4F1.5)
Donor diseases:
Stargardt Disease
RMCGENi020-A
(IPS15-00004)
Donor diseases:
Stargardt Disease
RMCGENi021-A
(IPS22-00087)
Donor diseases:
Stargardt Disease
SCTCi017-A
(IPS15-00006)
Donor diseases:
Stargardt disease
SCTCi018-A
(IPS15-00007)
Donor diseases:
Stargardt disease
NUIGi010-A
(LQTS009C2)
Donor diseases:
Long QT Syndrome 1
NUIGi010-B
(LQTS009C3)
Donor diseases:
Long QT Syndrome 1
NUIGi010-C
(LQTS009Cx)
Donor diseases:
Long QT Syndrome 1
HDZi001-A
(hiPSC NP0039)
Donor's gene variants:
TMEM43
Donor diseases:
arrhythmogenic right ventricular dysplasia 5
NUIGi006-A
(LQTS005C2, LQT005C2)
Donor diseases:
Long QT Syndrome 1
NUIGi006-B
(LQTS005C4, LQT005C4)
Donor diseases:
Long QT Syndrome 1
NUIGi006-C
(LQTS005Cx, LQT005Cx)
Donor diseases:
Long QT Syndrome 1
NUIGi007-A
(LQTS006C6, LQT006C6)
Donor diseases:
Long QT Syndrome 1
NUIGi007-B
(LQTS006C8, LQT006C8)
Donor diseases:
Long QT Syndrome 1
CSSi007-A
(Joub07 cl1, COR11-NG708)
Donor diseases:
Joubert syndrome
NUIGi009-B
(LQTS008C6)
Donor diseases:
Long QT Syndrome 1
NUIGi009-C
(LQTS008Cx)
Donor diseases:
Long QT Syndrome 1
NUIGi011-A
(LQTS010C3)
Donor diseases:
Long QT Syndrome 1
NUIGi011-B
(LQTS010C4)
Donor diseases:
Long QT Syndrome 1
NUIGi011-C
(LQTS010Cx)
Donor diseases:
Long QT Syndrome 1
NUIGi012-A
(LQT011C8)
Donor diseases:
Long QT Syndrome 2
NUIGi015-A
(LQT014C7)
Donor diseases:
Long QT Syndrome 3
NUIGi015-B
(LQT014C9)
Donor diseases:
Long QT Syndrome 3
NUIGi015-C
(LQT014C12)
Donor diseases:
Long QT Syndrome 3
NUIGi020-A
(LQT019C1)
Donor diseases:
Long QT Syndrome 2
NUIGi020-B
(LQT019C4)
Donor diseases:
Long QT Syndrome 2
NUIGi020-C
(LQT019Cx)
Donor diseases:
Long QT Syndrome 2
NUIGi003-A
(LQT002C1)
Donor diseases:
Long QT Syndrome 2
NUIGi004-A
(LQT003C1)
Donor diseases:
long QT syndrome 2
NUIGi005-A
(LQTS004C7, LQT004C7)
Donor diseases:
Long QT Syndrome 1
NUIGi005-B
(LQTS004C9, LQT004C9)
Donor diseases:
Long QT Syndrome 1
NUIGi005-C
(LQTS004Cx, LQT004Cx)
Donor diseases:
Long QT Syndrome 1
NUIGi008-A
(LQTS007C1)
Donor diseases:
Long QT Syndrome 1
NUIGi003-B
(LQT002C2)
Donor diseases:
Long QT Syndrome 2
NUIGi008-B
(LQTS007C2)
Donor diseases:
Long QT Syndrome 1
NUIGi008-C
(LQTS007Cx)
Donor diseases:
Long QT Syndrome 1
NUIGi009-A
(LQTS008C1)
Donor diseases:
Long QT Syndrome 1
LUMCi040-A
(LUMC0053iSCN01B)
Donor diseases:
Brugada syndrome
Last update 12th April 2024
Notes This is a GMP grade, autosomal recessive retinal dystrophy (ARRD) patient-specific, induced pluripotent stem cell line, carrying a homozygous point mutation within exon 44 of ABCA4 leading to Arg2030Ter. This mutation (c.6088C>T) results in premature truncation of the protein lacking C-terminal nucleotide binding domain. This iPSC line was generated by the reprogramming of donor skin-derived human dermal fibroblasts (HDFs) using GMP compliant processes, xeno-free reagents, cell therapy solutions grade defined culture components and integration-free CTS™ CytoTune™-iPS 2.1 Sendai Reprogramming Kit containing Sendai viral vectors encoding the human OCT4, SOX2, KLF4 and L-Myc genes. This iPSC line maintained proper colony morphology, expressed the stemness and pluripotency markers OCT4, SOX2, NANOG, KLF4, SSEA4, and exhibited a normal karyotype at passage 15.
User feedback
No feedback available yet.

Login to share your feedback, experiences or results with the research community.

Provider

Generator L.V. Prasad Eye Institute (LVPEI)
Owner L.V. Prasad Eye Institute (LVPEI)
Distributors
Derivation country India

External Databases

BioSamples SAMEA115172670
Cellosaurus CVCL_D6MX
Wikidata Q127382718

General Information

Publications
* Is the cell line readily obtainable for third parties?
Yes
Research use: allowed
Clinical use: not allowed
Commercial use: allowed

Donor Information

General Donor Information

Sex male
Age of donor (at collection) 25-29
Ethnicity Asian Indian (26 year old)

Phenotype and Disease related information (Donor)

Diseases A disease was diagnosed.
Stargardt Disease, Type 1 (STGD1), Autosomal Recessive Macular Dystrophy, Type 2 (ARMD2), Cone-Rod Dystrophy, Type 3 (CORD3), Juvenile Macular Dystrophy (JMD).
The donor is a carrier of a disease-associated mutation and affected.
Stage
Retinal degeneration and total blindness.
Synonyms
  • Stargardt 1
  • fundus flavimaculatus
  • Stargardt disease 1
  • Stargardt macular dystrophy
  • juvenile onset macular degeneration
show more synonyms
Family history Positive history of consanguinity
Is the medical history available upon request? Yes
Is clinical information available? Yes

Other Genotyping (Donor)

Is there genome-wide genotyping or functional data available?
No

Donor Relations

Other cell lines of this donor
All cell lines of this donor's relatives

External Databases (Donor)

BioSamples SAMEA115172671

Ethics

Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? Yes
Was the consent voluntarily given? Yes
Has the donor been informed that participation will not directly influence their personal treatment? Yes
Can you provide us with a copy of the Donor Information Sheet provided to the donor? No
Please provide contact information of the holder of the original Donor Information Sheet. indumathi@lvpei.org
Do you (Depositor/Provider) hold the original Donor Consent Form? Yes
Alternatives to consent are available? No
Is there other documentation provided to the donor for consenting purposes? No
Confirm that consent was obtained by a qualified professional Yes
Has the donor agreed to be re-contacted? Unknown
Has the donor been informed about how her/his data will be protected? Yes
Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. pseudonymised
Does consent explicitly allow the derivation of pluripotent stem cells? Yes
Does consent expressly prevent the derivation of pluripotent stem cells? No
Does consent pertain to a specific research project? Yes
Details on restriction to research project Generation of induced pluripotent stem cells (iPSCs) of healthy individuals and patients with inherited eye diseases (IEDs).
Does consent permit unforeseen future research, without further consent? Yes
Does the consent permit uses of donated embryo/tissue or derived cell line intended for clinical treatment or human applications? No
Does consent expressly prevent development of commercial products? No
Does consent expressly prevent financial gain from any use of the donated embryo/tissue, including any product made from it? No
Does consent expressly permit storage of donated embryo/tissue for an unlimited time? No
Does consent expressly permit storage of cells derived from the donated embryo/tissue for an unlimited time? Yes
Does consent prevent the DONATED BIOSAMPLE from being made available to researchers anywhere in the world? No
Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? No

Does consent permit research by

an academic institution? Yes
a public organisation? Yes
a non-profit company? Yes
a for-profit corporation? Yes
Does consent expressly permit collection of genetic information? Yes
Does consent expressly permit storage of genetic information? Yes
Does consent prevent dissemination of genetic information? No
Has the donor been informed that their donated biosample or derived cells may be tested for the presence of microbiological agents / pathogens? Yes
Has the donor consented to receive information discovered during use of donated embryo/tissue that has significant health implications for the donor? Yes
How may genetic information associated with the cell line be accessed? Controlled Access
Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? No
Does the consent anticipate that the donor will be notified of results or outcomes of any research involving the donated samples or derived cells? No
Does the consent permit the donor, upon withdrawal of consent, to stop the use of the derived cell line(s) that have already been created from donated samples? Yes
Does the consent permit the donor, upon withdrawal of consent, to stop delivery or use of information and data about the donor? Yes
Does consent permit access to medical records of the donor? No
Does consent permit access to any other source of information about the clinical treatment or health of the donor? No
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? Yes
Name of accrediting authority involved? IEC,IC-SCR
Approval number IEC : LEC-08011; LEC-BHR-P-06-22-878; IC-SCR : 04-15-016; 05-21-013.
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the PROPOSED PROJECT, involving use of donated embryo/tissue or derived cells? Yes
Name of accrediting authority involved? IEC,IC-SCR
Approval number IEC : LEC-08011; LEC-BHR-P-06-22-878; IC-SCR : 04-15-016; 05-21-013.
Do you have obligations to third parties in regard to the use of the cell line? No
Are you aware of any further constraints on the use of the donated embryo/tissue or derived cells? No
Is there an MTA available for the cell line? Yes
For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? Addgene
Are you aware of any constraints on the use or distribution of the cell line from the owner or any parties identified in the query above? Yes
Constraints for use or distribution For research use only

hIPSC Derivation

General

Source cell type
Dermal fibroblasts are the major cell type in dermis and are commonly accepted as terminally differentiated cells.
Source cell origin
An organ that constitutes the external surface of the body. It consists of the epidermis, dermis, and skin appendages.
Synonyms
  • Skin
  • Human Skin
  • SKIN
  • Integument
  • Skin, total
  • Skin, NOS
  • Skin structure (body structure)
  • entire skin
  • skin of body
  • skin organ
show more synonyms
Source cell type (free text) Full thickness skin punch biopsy was taken from the retro auricular surface to establish Human Dermal Fibroblast (HDF) cultures.
Age of donor (at collection) 25-29
Collected in 2008
Passage number reprogrammed 4

Reprogramming method

Vector type Non-integrating
Vector Sendai virus
Genes
Is reprogramming vector detectable?
No
Methods used
RT-PCR
Notes on reprogramming vector detection The SeV encoded transgene-specific transcripts were undetectable beyond passage 11 by RT-PCR

Vector free reprogramming

Type of used vector free reprogramming factor(s)
None

Other

Selection criteria for clones Manual picking and passaging till Passage 5. The stably expanding clones are subsequently passaged as cell suspensions prepared using 1X cell dissociation solution (1X DPBS containing 0.5 mM EDTA and 30 mM NaCl) treatment for 6-7 minutes.
Derived under xeno-free conditions
Yes
Derived under GMP?
No
Available as clinical grade?
Yes

Culture Conditions

Surface coating Vitronectin
Feeder cells
No
Passage method Enzyme-free cell dissociation
EDTA
CO2 Concentration 5 %
Medium Essential 8™
Has Rock inhibitor (Y27632) been used at passage previously with this cell line?
Yes
Has Rock inhibitor (Y27632) been used at cryo previously with this cell line?
No
Has Rock inhibitor (Y27632) been used at thaw previously with this cell line?
Yes

Characterisation

Analysis of Undifferentiated Cells
Marker Expressed Immunostaining RT-PCR Flow Cytometry Enzymatic Assay Expression Profiles
POU5F1 (OCT-4)
Yes
NANOG
Yes
KLF4
Yes
hTERT
Yes
SSEA-4
Yes
Score:
Marker Present Absent
mCpG
OCT4
Differentiation Potency
Endoderm
Ont Id: UBERON_0000925
In vitro spontaneous differentiation
Marker Expressed
GATA6
Yes
AFP
Yes
Mesoderm
Ont Id: UBERON_0000926
In vitro spontaneous differentiation
Marker Expressed
ACTA2
Yes
MSX2
Yes
Ectoderm
Ont Id: UBERON_0000924
In vitro spontaneous differentiation
Marker Expressed
SOX1
Yes
PAX6
Yes

Microbiology / Virus Screening

Mycoplasma Negative

Genotyping

Karyotyping (Cell Line)

Has the cell line karyotype been analysed?
Yes
Normal karyotype, 46, XY
Passage number: 15
Karyotyping method: G-Banding

Other Genotyping (Cell Line)